Ocumension Therapeutics (1477) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

SciClone Pharmaceuticals (Holdings) Ltd.

Beijing Tong Ren Tang Chinese Medicine Co., Ltd.

Livzon Pharmaceutical Group, Inc.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shandong Boan Biotechnology Co., Ltd.

Ocumension Therapeutics

Cutia Therapeutics

Lepu Biopharma Co., Ltd.

RemeGen Co., Ltd.

Everest Medicines Ltd.

InnoCare Pharma Ltd.

Why is Ocumension Therapeutics ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

Poor long term growth as Operating profit has grown by an annual rate 2.66% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -303.35

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 66.00%, its profits have risen by 31.6%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ocumension Therapeutics for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Ocumension Therapeutics

66.0%

0.33

65.98%

Hang Seng Hong Kong

27.36%

1.03

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

201.12%

EBIT Growth (5y)

2.66%

EBIT to Interest (avg)

-303.35

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.20

Sales to Capital Employed (avg)

0.07

Tax Ratio

0.38%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.85

EV to EBIT

-20.00

EV to EBITDA

-28.14

EV to Capital Employed

2.06

EV to Sales

14.68

PEG Ratio

Dividend Yield

ROCE (Latest)

-10.31%

ROE (Latest)

-7.25%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Bullish

Moving Averages

Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Ocumension Therapeutics

Net Sales

Highest at HKD 270.86 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (HKD MM)

Net Sales

At HKD 270.86 MM has Grown at 75.73%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (HKD MM)

Operating Profit

Highest at HKD -100.42 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (HKD MM)

Operating Profit Margin

Highest at -37.07 % and Grown

In each period in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Operating Cash Flow

Highest at HKD -334.59 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Pre-Tax Profit

Highest at HKD -126.58 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

Highest at HKD -127.4 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

EPS

Highest at HKD -0.18

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Inventory Turnover Ratio

Highest at 5.22%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 4.28%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Depreciation

Highest at HKD 57.68 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Depreciation

At HKD 57.68 MM has Grown at 50.17%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Ocumension Therapeutics

Cash and Eqv

Lowest at HKD 818.6 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -19.7 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 23.64% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales